Skip to main content
. 2010 Sep 29;84(23):12245–12254. doi: 10.1128/JVI.01603-10

FIG. 3.

FIG. 3.

Functional characterization of the transmitted/founder Sab92018ivTF clone. (A) TZM-bl indicator cells were infected with the indicated SIVagm molecular clones. Infections were performed with virus stocks containing 10 ng of p27 antigen. Panels A and D show average values of triplicate infections ± standard deviations (SD). ivTF, SIVagmSab92018ivTF. (B) Replication of SIVagmSab92018ivTF in Molt-4 clone 8 cells. OD, optical density. (C) Western blot analysis of cellular extracts of 293T cells transfected with the indicated molecular clones of SIVagmSab (left) and virions pelleted from the culture supernatant (right). (D) TZM-bl cells were left untreated (control) or were pretreated with specific inhibitors of CCR5 (Maraviroc), CXCR4 (AMD3100), or a combination thereof prior to infection with the indicated molecular clones of HIV-1 or SIV. (E) Coreceptor usage by SIVagmSab92018ivTF and the indicated control viruses tested in GHOST cells expressing CD4 alone (parental) or together with CCR5, CXCR4, or the orphan receptors BOB/GPR15 and BONZO/STRL33. All infectivity data were confirmed in one or two independent experiments.